Company intelligence / Profile preview
Yaoyou Pharmaceutical
Chongqing, Chongqing, Chinaen.yaopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
YP05002, an oral small molecule GLP-1R agonist, is in Phase 1 clinical trials for chronic weight management, type 2 diabetes, obesity, and related conditions. Licensed exclusively to Pfizer globally with ongoing Phase 1 trial completion by Yaoyou.
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Pfizer (exclusive global license for YP05002)
Beyond the preview
Go deeper on Yaoyou Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yaoyou Pharmaceutical.